VectorialDATA
Stocks/MRK

MRK — Merck & Co., Inc.

HealthcareNorth AmericaUnited StatesBlockchain certified

Price when we picked it (Sep 15, 2026)

$143.85

Target: $152.96 (+6.3%)

P/E Ratio

114.8

P/E Forward

15.0

Dividend

2.35%

Market Cap

$354.2B

EPS

$1.25

Consensus

Buy

What they do

Merck & Co. (Rahway, New Jersey; CEO Rob Davis; ~75,000 employees; known as MSD outside the US and Canada) is one of the world's largest pharmaceutical companies. Its heart is Keytruda, the immunotherapy that helps the immune system attack cancer: $31.7 billion in 2025 and $8.4 billion in Q2 2026 (~half of revenue), including Keytruda Qlex, the injectable version given in ~1 minute instead of a 30-minute infusion. Next come vaccines (Gardasil against HPV, $1.17 billion in the quarter; Capvaxive against pneumococcus), Winrevair (pulmonary hypertension, from the $11.5 billion Acceleron acquisition), Welireg (kidney cancer) and an animal health business of $1.8 billion a quarter (+8%).

Since 2025 it has bought its next generation: Verona Pharma (~$10 billion, closed October 7, 2025; Ohtuvayre for COPD, $204 million in the quarter), Cidara (~$9.2 billion; CD388, flu prevention in Phase III) and Terns ($6.8 billion; MK-4208 for chronic myeloid leukemia).

2026 brought key approvals: Lipfendra (enlicitide, July 16), the first and only once-daily PCSK9 pill to lower LDL cholesterol — by up to 60% —, new Keytruda combinations in kidney, bladder and triple-negative breast cancer; and on August 19 the personalized messenger-RNA therapy intismeran (with Moderna) met its Phase III goals in melanoma — the first of its kind to do so.

Why we like it

Three reasons.

  • KEYTRUDA'S REPLACEMENT ALREADY SHOWS IN THE NUMBERS: in Q2 Winrevair sold $588 million (+75%), Welireg $271 million (+67%), Capvaxive $184 million (+42%) and Ohtuvayre $204 million; 2026 sales guidance rose to $66.3–67.3 billion (from $65.5–67.0 billion in February). On September 14, at the Morgan Stanley conference, management said its goal of more than $70 billion in revenue from recent launches and pipeline by the mid-2030s 'looks conservative' (oncology now >$25 billion) and describes Keytruda's patent expiry as 'a hill, not a cliff'.
  • A PIPELINE THAT JUST DELIVERED: Lipfendra approved (~30 million US patients treated but not at their cholesterol goal), intismeran positive in Phase III melanoma (August 19; in Phase II it cut the risk of relapse or death by 49% at 5 years), sacituzumab tirumotecan met its Phase III goal in endometrial cancer and Keytruda Qlex is moving patients to the injectable version.
  • CHEAP BEHIND THE ACCOUNTING EFFECT: the 114.8x price vs. profit reflects one-time acquisition charges — 2026 adjusted EPS guidance ($2.66–2.76) includes $6.05 per share of charges (Cidara $3.62, Terns $2.31, other $0.12); without them it would be ~$8.71–8.81, and the 2027 consensus is $9.55 → at $143.85 it trades at 15x. It pays $3.40 a year (2.35%), raised 4.9% in November 2025, 15 straight years of increases. Buy consensus from 28 analysts, average target $152.96 (+6.3%), with September raises: HSBC $172, BofA $166, Guggenheim $170, DBS $180.

Key Risk

#1: Keytruda's patent expires in 2028. It is ~half of revenue; the thesis needs Winrevair, Lipfendra, vaccines, acquisitions and new oncology drugs to fill the gap in time — the company promises 'a hill, not a cliff', but it is a promise. Others:

  • generics already in 2026: Januvia/Janumet (also with a government-set price), Bridion and Dificid take away ~$2.5 billion this year;
  • Gardasil in China: demand collapsed and Merck has halted shipments since 2025 — the vaccine is no longer a growth engine;
  • acquisition execution: ~$26 billion on Verona, Cidara and Terns since 2025, with ~$14.7 billion booked as expense in 2026 — they have to work; gross margin fell 1.1 points in the quarter;
  • US pricing policy: the December 2025 'most-favored-nation' deal (Januvia from $330 to $100 on TrumpRx) and reimbursement pressure keep shifting;
  • no longer beaten down: up ~75% in a year, trading near its high ($156.92), and the average target implies only +6%; Lipfendra will have a slow start (full coverage around end of 2027).

This is educational and informational content, not financial advice. Always consult a qualified financial advisor before making investment decisions.

Vectorial Data picked MRK on Sep 15, 2026 at $143.85.

Full Research

What it does. Merck & Co. (NYSE: MRK; Rahway, New Jersey; Chairman and CEO Rob Davis; ~75,000 employees at end-2025; MSD outside the US and Canada) is a global pharma with two segments: Pharmaceutical ($14.76 billion in Q2 2026, +5%) and Animal Health ($1.8 billion, +8%). Pillar: Keytruda/Keytruda Qlex (cancer immunotherapy; $31.7 billion in 2025, +7%; $8.4 billion in the quarter, ~half of revenue). Growth: Winrevair (pulmonary arterial hypertension, via Acceleron for $11.5 billion), Welireg (kidney), Capvaxive (pneumococcus), Ohtuvayre (COPD, via Verona), Enflonsia (RSV in infants, just launched), Lipfendra (cholesterol). Vaccines: Gardasil/Gardasil 9.

Results (Q2 2026, August 4). Revenue $16.61 billion (+5% / +4% excluding currency), above consensus (~$16.36 billion). Keytruda $8.4 billion (+5%; Qlex $463 million); Winrevair $588 million (+75%); Welireg $271 million (+67%); Gardasil $1.17 billion (+4%); Capvaxive $184 million (+42%); Ohtuvayre $204 million; Animal Health $1.8 billion (+8%). EPS: −$0.54 reported and −$0.13 adjusted, both due to the one-time $2.31 per share charge (Terns); without that charge adjusted EPS would be around $2.18. R&D spending $9.7 billion (vs $4.0 billion a year earlier, due to the charge). Gross margin −1.1 points on inventory reserves. 2026 guidance: sales $66.3–67.3 billion (raised from $65.8–67.0 billion; $65.5–67.0 billion in February); adjusted EPS $2.66–2.76 including one-time charges of $3.62 (Cidara, $9.0 billion), $2.31 (Terns, $5.7 billion) and $0.12 (financing/MK-4208); tax rate 35–36%. 2025 base: sales $65.0 billion (+1%).

2026 pipeline. Lipfendra (enlicitide) FDA-approved July 16: first once-daily PCSK9 pill, lowers LDL by up to 60%; target ~30 million US patients not at goal; full commercial coverage expected around end-2027. Intismeran autogene + Keytruda (with Moderna): Phase III INTerpath-001 met recurrence-free and distant-metastasis-free survival (August 19) — the first positive Phase III for an individualized neoantigen therapy and for an mRNA cancer therapy; the stock rose more than 12% in one August session. Sacituzumab tirumotecan (TroFuse-005) succeeded in endometrial cancer (17 Phase IIIs under way). Keytruda approved in new combinations (kidney, muscle-invasive bladder, advanced triple-negative breast). Calderasib (KRAS G12C) with Breakthrough Therapy designation and a Phase III with Keytruda Qlex. Tulisokibart succeeded in ulcerative colitis (discontinued in systemic sclerosis). Islatravir/lenacapavir (with Gilead): once-weekly oral HIV treatment with Phase III data. At the Morgan Stanley conference (September 14) management said the >$70 billion mid-2030s goal for revenue from recent launches and pipeline 'looks conservative' (oncology >$25 billion) and that intismeran and the MK-2010 bispecific were not included.

Acquisitions. Verona Pharma (~$10 billion, closed October 7, 2025; Ohtuvayre), Cidara Therapeutics (~$9.2 billion, $221.50 per share; CD388 against flu, Phase III with Breakthrough Therapy designation), Terns Pharmaceuticals ($6.8 billion, closed in Q2 2026; MK-4208 for chronic myeloid leukemia).

Dividend. $0.85 quarterly ($3.40 a year), raised 4.9% from $0.81 in November 2025; 15 straight years of increases. ≈2.35% at the purchase price. Record date for the October 7 payment: September 15, 2026 — today's purchase does not collect that payment; the next one it does. Against expected 2027 EPS ($9.55) the dividend is ~36%.

US and policy. Merck was one of the nine drugmakers in the 'most-favored-nation' deal announced December 19, 2025: Medicaid prices tied to developed countries, direct sales via TrumpRx (Januvia from $330 to $100) and tariff relief, in exchange for US manufacturing investment (≥$150 billion across the nine). 2026 generics: Januvia/Janumet, Bridion (US exclusivity to July 2026) and Dificid take ~$2.5 billion of revenue this year.

Stock. $143.85 at the open (September 15, 2026); market cap ~$354.2 billion; 52-week range $77.58–$156.92; ~+75% in a year. P/E 114.8x TTM (distorted by acquisition charges) / 15.0x forward. Buy consensus (28 analysts); average target $152.96 (range $105–186), +6.3%. September: HSBC raised to $172, Guggenheim to $170, Leerink to $161, BofA $166, DBS $180.

Risks. (1) Keytruda patent (2028), ~half of revenue; management expects 'a hill, not a cliff' and acknowledges slower Keytruda growth from 2027. (2) 2026 generics (~$2.5 billion). (3) Gardasil in China: shipments halted since 2025 on collapsing demand. (4) Execution on ~$26 billion of acquisitions; ~$14.7 billion in one-time charges in 2026. (5) US pricing policy (most-favored-nation, TrumpRx, government-set prices). (6) Valuation no longer depressed after +75% in a year; average target only +6%. (7) Slow Lipfendra start; binary readouts (tulisokibart data around late 2026 or early 2027).

More picks in Healthcare

See all Healthcare picks →

More picks from United States

See all picks from United States →
Researched: Sep 15, 2026Updated: Sep 15, 2026Next review: Mar 15, 2027

This is not financial advice. Consult a certified financial advisor.

The author may hold positions in the securities discussed.

Past performance does not guarantee future results.